Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes
Hypomethylating agents (HMAs) are widely used in the treatment of myelodysplastic syndromes myelodysplastic syndromes: (my-eh
Myelodysplastic Syndromes (MDS)
Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)
Purpose: TP53-mutated (TP53m) myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS
Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantat
Background: Immune checkpoint inhibitors (ICIs) are being used after allogeneic hematopoietic stem cell transplantation (alloHCT) to reverse immune dysfunction.
Joshua Zeidner, MD
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
About
Dr. Zeidner's research interests include discovering innovative methods to improve outcomes, drug discovery and development, and designing clinical trials in acute myeloid leukemia (AML) myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs). He leads the Leukemia Clinical Trials Research Protocol Office Disease (POD) Group where we have a multitude of cutting-edge clinical trials for acute leukemia, MDS, and MPNs. Dr. Zeidner's the Principal Investigator of industry-sponsored, investigator-initiated, and academic collaborative clinical trials evaluating novel agents in MDS
Katherine Tarlock, MD
Institution
Seattle Children's Hospital
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Pediatric
About
Katherine Tarlock, M.D., is a board certified physician at Seattle Children’s Hospital and a UW assistant professor of pediatrics. Dr. Tarlock believes the privilege of caring for patients and families during challenging medical diagnoses is what drew her to this field and continues to be the best part of her job. She is dedicated to advancing our understanding of leukemia and being able to offer every child and family the best care. Dr. Tarlock earned her M.D. at Chicago Medical School. She is board certified in both Pediatrics and Pediatric Hematology/Oncology.
Stephan Paul, MD, JD
Institution
J. W. Ruby Memorial Hospital
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Myelodysplastic Syndromes (MDS)
Pediatric
Jane Liesveld, MD
Institution
Strong Memorial Hospital
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Brian Shaffer, MD
Institution
Memorial Sloan Kettering Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
About
Dr. Shaffer is a board certified hematologist specializing in bone marrow transplantation for leukemia, myelodysplastic syndromes, lymphoma, and other bone marrow disorders. He works in a collaborative fashion with other members of our team to provide comprehensive cancer care at Memorial Sloan Kettering Cancer Center. His research focuses on the role of Natural Killer (NK) cells in outcomes after transplantation. NK cells are white blood cells that have anti-tumor and anti-infection properties. His goal is to improve the transplantation process for patients via understanding and optimizing NK
Robert Hasserjian, MD
Institution
Massachusetts General Hospital
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
About
Dr. Hasserjian's clinical work and research focus on myeloid neoplasia. He has served on the Executive Committee of the Society for Hematopathology and on the Education Committee of the United States and Canadian Academy of Pathology. Dr. Hasserjian is a member of the Pathology Advisory Committee for the World Health Organization Classification of Myeloid Neoplasms. Dr. Hasserjian is a dedicated medical educator, and director of the Hematopathology Fellowship at Massachusetts General Hospital.
Luspatercept in the treatment of lower-risk myelodysplastic syndromes
Transforming growth factor growth factor: A substance made by the body that stimulates the bone marrow to produce blood cells.